Literature DB >> 31659660

Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling.

Bansri Desai1, Kyungwan Hong1, John H Powers2, Peter Doshi3.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31659660      PMCID： PMC6957611          DOI： 10.1007/s11606-019-05460-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  3 in total

Review 1.  Clinicians' Expectations of the Benefits and Harms of Treatments, Screening, and Tests: A Systematic Review.

Authors:  Tammy C Hoffmann; Chris Del Mar
Journal:  JAMA Intern Med       Date:  2017-03-01       Impact factor: 21.873

2.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Authors:  Nicholas S Downing; Jenerius A Aminawung; Nilay D Shah; Harlan M Krumholz; Joseph S Ross
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

Review 3.  Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review.

Authors:  Tammy C Hoffmann; Chris Del Mar
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873
  3 in total
  2 in total

1.  Comparative analysis of PIM criteria and drug labels in the elderly.

Authors:  Yanwen Wang; Xiaohe Li; Shengnan Zhuo; Xinling Liu; Wei Liu
Journal:  Eur J Clin Pharmacol       Date:  2022-01-04       Impact factor: 2.953

2.  Consensus on Language for Advance Informed Consent in Health Care-Associated Pneumonia Clinical Trials Using a Delphi Process.

Authors:  Amy Corneli; Sara B Calvert; John H Powers; Teresa Swezey; Deborah Collyar; Brian Perry; John J Farley; Jonas Santiago; Helen K Donnelly; Carisa De Anda; Katelyn Blanchard; Vance G Fowler; Thomas L Holland
Journal:  JAMA Netw Open       Date:  2020-05-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.